Antiresorptive Therapies for Osteoporosis
Stuart Weinerman1, Gianina L Usera1
1Division of Endocrinology & Diabetes, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, 865 Northern Boulevard, Suite 203, Great Neck, New York 11021, USA.
Oral and Maxillofacial Surgery Clinics of North America
|September 29, 2015
Summary
Osteoporosis treatment with bisphosphonates is effective but carries risks. Long-term use, over 10 years, increases the chance of serious side effects like atypical femur fractures.
Area of Science:
- Bone health and metabolic disorders
- Pharmacological treatments for osteoporosis
Background:
- Osteoporosis is a prevalent condition characterized by low bone density, leading to increased fracture risk.
- Antiresorptive medications, particularly bisphosphonates, are highly effective treatments for osteoporosis.
- While bisphosphonates are well-studied for efficacy and safety, concerns exist regarding long-term use.
Purpose of the Study:
- To review the established efficacy and safety of bisphosphonate therapy for osteoporosis.
- To highlight emerging evidence on the risks associated with prolonged bisphosphonate treatment.
Main Methods:
- Review of existing scientific literature on bisphosphonate therapy in osteoporosis.
- Analysis of data concerning the long-term safety profile of bisphosphonates.
Main Results:
- Bisphosphonates demonstrate significant efficacy in managing osteoporosis.
- Extended use of bisphosphonates (over 10 years) is associated with an elevated risk of specific adverse events.
- Key serious side effects include atypical femur fractures and osteonecrosis of the jaw.
Conclusions:
- Bisphosphonates are a cornerstone of osteoporosis management due to their effectiveness.
- Clinicians must carefully weigh the benefits against the potential serious risks of long-term bisphosphonate therapy.
- Monitoring for and awareness of atypical femur fractures and osteonecrosis of the jaw are crucial in patients on long-term treatment.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
4.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.8K
01:40Bone Remodeling
41.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.1K
01:17Hormones and Bone Tissue
4.2K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:29Bone Disorders
7.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
7.8K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K